If your goal is lower cardiovascular risk, BMI alone is not enough. I’d look past body weight and focus on what is driving risk: prior ASCVD, kidney disease, HFpEF, diabetes control, triglycerides, inflammation, and waist size.
Here’s the short answer:
- GLP-1 receptor agonists have the deeper hard-outcomes record, especially for ASCVD and CKD
- Tirzepatide tends to deliver larger average drops in weight, A1C, triglycerides, and blood pressure
- Semaglutide 2.4 mg cut MACE by 20% in SELECT, even in many people who did not lose much weight
- Tirzepatide has strong marker data and newer event data, including HFpEF results and CVOT noninferiority vs. dulaglutide
- The best pick depends on the patient’s main risk pattern, not just BMI
So if I’m choosing between them, I’d keep it simple:
- Pick a GLP-1 RA when established ASCVD or CKD is the main issue
- Pick tirzepatide when severe obesity, insulin resistance, high triglycerides, fatty liver, or HFpEF are driving residual risk
- For both, I’d track more than weight: waist circumference, blood pressure, lipids, A1C, eGFR, urine albumin, hs-CRP, and adherence
Bottom line: GLP-1 drugs lead on event history; tirzepatide leads on average metabolic change. This comparison works best when you match the drug to the risk you’re trying to lower.
GLP-1 vs Tirzepatide: CV Risk Reduction Comparison
ACC 26: SURPASS-CVOT - Tirzepatide Versus Dulaglutide on Cardiorenal Outcomes in Type 2 Diabetes
sbb-itb-7164bd9
Quick Comparison
| Topic | GLP-1 Receptor Agonists | Tirzepatide |
|---|---|---|
| Main strength | More event-based CV data | Larger average metabolic effects |
| Best fit | ASCVD, CKD, secondary CV prevention | Severe obesity, high triglycerides, insulin resistance, fatty liver, HFpEF |
| Weight loss | Strong | Usually more |
| A1C drop | Strong | Usually more |
| MACE data | More mature | Newer, still building |
| Kidney data | Stronger | Less mature |
| HFpEF data | Positive | Positive |
| Monitoring | GI effects, renal function, retinopathy risk in some patients, adherence | Same, with extra focus on triglycerides, liver markers, and titration tolerance |
I’d use the rest of the article to sort out which drug fits which patient once BMI stops being the whole story.
GLP-1 Receptor Agonists: Cardiovascular Effects Beyond Weight Loss
GLP-1 receptor agonists have the deepest cardiovascular outcomes data in incretin therapy. And the upside goes beyond weight loss alone. Across many trials, the drop in events is bigger than weight loss by itself would suggest. That’s the bar tirzepatide has to clear.
Mechanisms Relevant to ASCVD, Kidney Risk, and Heart Failure
These drugs improve glycemia in a few key ways: they increase glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying. They also support endothelial function through nitric oxide signaling, lower oxidative stress, and lead to modest natriuresis plus small reductions in blood pressure.
The kidney effects matter too. GLP-1 RAs reduce albuminuria and slow eGFR decline through lower intraglomerular pressure, better renal microvascular endothelial function, and less inflammation. Those gains still show up even after accounting for changes in A1c and body weight.
Marker Changes and Outcomes Data for Clinical Use
Marker changes tend to be modest. But they move in the same direction as the event data, and that’s what gives them clinical weight.
| Marker | Representative change across trials |
|---|---|
| Systolic blood pressure | ~3–5 mm Hg reduction |
| Triglycerides | ~15–20% reduction |
| hsCRP | ~30–40% reduction |
| eGFR decline | Slowed vs. placebo |
| Urine albumin-to-creatinine ratio | Reduced |
In SELECT, semaglutide 2.4 mg cut hsCRP by 39.1% and reduced MACE by 20% (HR 0.80; 95% CI 0.72–0.90) in adults with obesity and established CVD without diabetes. In type 2 diabetes, SUSTAIN-6 showed subcutaneous semaglutide reduced three-point MACE by 26% (HR 0.74; 95% CI 0.58–0.95) versus placebo.
Meta-analyses across long-acting GLP-1 RA trials show about a 14% relative risk reduction in MACE, a 17% reduction in composite kidney outcomes, and a 12% reduction in all-cause mortality. Put simply, the biomarker shifts may look small on paper, but the event reduction is what clinicians care about most.
When GLP-1 Receptor Agonists Are the Right Fit in U.S. Practice
In U.S. practice, GLP-1 RAs are used for ASCVD, CKD, and HFpEF risk reduction, not just BMI. Four patient profiles stand out:
- Type 2 diabetes with established ASCVD: Use a GLP-1 RA with proven CV benefit - semaglutide, liraglutide, or dulaglutide - regardless of BMI.
- Overweight or obesity (BMI ≥27 kg/m²) with established CVD but no diabetes: SELECT directly supports semaglutide 2.4 mg for secondary prevention in this group, addressing residual cardiometabolic risk beyond weight.
- Type 2 diabetes with CKD or albuminuria: When SGLT2 inhibitors aren’t tolerated or don’t give enough protection, GLP-1 RAs offer meaningful renal and cardiovascular protection against residual risk.
- Obesity-related HFpEF: STEP-HFpEF showed better symptoms, 6-minute walk distance, KCCQ scores, and reductions in NT-proBNP and CRP, pointing to lower inflammatory and hemodynamic risk.
Before starting treatment, document waist circumference, blood pressure, fasting lipids, hsCRP, A1c, eGFR, and urine albumin-to-creatinine ratio. In HFpEF or high cardiac-risk patients, also check NT-proBNP and NYHA functional class.
Then reassess at 3 to 6 months, looking at glycemia, weight, blood pressure, and lipids. Renal function and albuminuria should be checked at least once a year.
Tirzepatide should be measured against this GLP-1 baseline. Its stronger metabolic effects are clear. The open question is whether that translates into added cardiovascular benefit.
Tirzepatide: What Dual GIP/GLP-1 Agonism Adds to Cardiometabolic Risk Reduction
What Dual GIP/GLP-1 Signaling Means Clinically
Tirzepatide is a dual GIP/GLP-1 agonist. That makes it different from standard GLP-1 receptor agonists, which act on GLP-1 signaling alone.
In practice, dual signaling seems to improve appetite control, insulin secretion, and fat oxidation. GIP receptor activation may strengthen GLP-1 effects in those same areas, which can help with fat handling and overall metabolic control. At the patient level, that has been linked to larger shifts in weight, glycemia, lipids, and inflammatory markers.
The key clinical issue is pretty simple: does this broader signaling lead to more cardiometabolic risk reduction than GLP-1 therapy alone?
Risk-Marker Changes and Current Cardiovascular Outcomes Data
Tirzepatide has consistently shown larger changes in weight and glycemia than GLP-1 monotherapy. In SURPASS-2, tirzepatide 15 mg lowered HbA1c by 2.46% and reduced body weight by about 11.2 kg, compared with 1.86% and 5.7 kg with semaglutide 1 mg. In SURMOUNT-1, mean weight loss reached 20.9% at 72 weeks.
It also affects a group of cardiometabolic markers that clinicians care about, not just the scale and A1c.
| Marker | Tirzepatide effect |
|---|---|
| Triglycerides | ~20% to 30% reduction vs. placebo/comparators |
| Systolic blood pressure | About −5 to −7 mmHg across SURPASS/SURMOUNT |
| Liver fat (MRI) | 8.09% absolute reduction at 15 mg in SURPASS-3 MRI |
| hsCRP | −38.8% at 52 weeks vs. −5.9% with placebo in SUMMIT |
| HbA1c | Up to −2.07% to −2.46%, depending on trial |
Taken together, those shifts look larger than what you'd expect from weight loss alone.
Cardiovascular outcomes data also look good, although the evidence base is still maturing. In SUMMIT, adults with obesity and HFpEF had fewer events of cardiovascular death or worsening heart failure with tirzepatide than with placebo, 9.9% versus 15.3%. They also had better quality of life and exercise capacity. In SURPASS-4, tirzepatide did not increase MACE versus insulin glargine, and the numerical trend favored tirzepatide. SURPASS-CVOT, published in 2025, adds longer-term event-based data in type 2 diabetes.
So the picture at this stage is pretty clear: tirzepatide has strong biomarker data and growing outcomes data, but it does not have the longest cardiovascular track record.
Which Patients Are Most Likely to Benefit From Tirzepatide
These effects matter most in patients whose cardiovascular risk stays high even after some weight loss. Tirzepatide tends to make the most sense when residual risk is tied to obesity, dyslipidemia, fatty liver, or HFpEF, not just BMI by itself.
Patients most likely to benefit include:
- Adults with BMI ≥30 kg/m² and at least two metabolic syndrome features, such as elevated triglycerides, low HDL-C, hypertension, or impaired fasting glucose
- Patients with type 2 diabetes and HbA1c ≥8% despite current therapy, especially when obesity is also present and there is a need to reduce insulin or sulfonylurea use
- Individuals with hypertriglyceridemia, atherogenic dyslipidemia, or elevated non-HDL cholesterol who need more than a modest lipid change
- Patients with fatty liver or other ectopic fat, including elevated liver enzymes or imaging-confirmed hepatic steatosis/NAFLD/MASH, where liver fat reduction may matter clinically
- Adults with obesity-related HFpEF
Monitoring still matters. At baseline and follow-up, track triglycerides, blood pressure, liver enzymes, renal function, and GI tolerance. In patients taking insulin or sulfonylureas, watch closely for hypoglycemia as glycemia improves. In HFpEF, keep an eye on volume status and GI tolerability during dose titration. In SUMMIT, treatment discontinuation with tirzepatide was about 6.3%.
Those details help show where tirzepatide may offer more than GLP-1 therapy alone.
GLP-1 vs Tirzepatide: Direct Clinical Comparison for CV Risk Reduction
Mechanism, Markers, and Outcomes: Side-by-Side
The core difference comes down to broader mechanism vs. deeper outcomes data.
GLP-1 receptor agonists act through a single receptor pathway that has been studied at length in large cardiovascular outcomes trials. Tirzepatide adds GIP receptor agonism on top of GLP-1 receptor agonism, and that added pathway seems to drive more weight loss and broader metabolic effects. Both drug types can lower residual cardiometabolic risk beyond weight loss alone, but they don't get there in the same way.
That matters in practice. The question isn't just which drug moves lab values more. It's which one is more likely to lower residual ASCVD, kidney, and HF risk for the person sitting in front of you.
And here's the catch: bigger marker changes don't always mean better event reduction.
Semaglutide reduced 3-point MACE by 26% in SUSTAIN-6 and by 20% in SELECT, which enrolled patients with obesity and prior CVD but no diabetes. In SURPASS-CVOT, tirzepatide was noninferior to dulaglutide for 3-point MACE and showed about an 8% relative reduction in MACE plus a 16% reduction in all-cause mortality. Those are meaningful findings. At the same time, tirzepatide's event-based data is still newer and not as deep as the GLP-1 class overall.
| Feature | GLP-1 Receptor Agonists | Tirzepatide (Dual GIP/GLP-1) |
|---|---|---|
| Mechanism | Selective GLP-1 receptor agonism | Dual GIP + GLP-1 receptor agonism |
| MACE evidence | Selected GLP-1 RAs (semaglutide, liraglutide, dulaglutide) have the strongest event-based CVOT evidence | Newer evidence; SURPASS-CVOT supports noninferiority vs. dulaglutide |
| Weight loss | Meaningful, but generally less than tirzepatide | Greater average weight loss |
| HbA1c reduction | Significant | Often larger |
| Blood pressure and lipids | Improves blood pressure and lipid profile | Often larger improvements, especially triglycerides |
| Inflammation | Lowers inflammatory markers such as hs-CRP | Also lowers inflammatory markers |
| Kidney outcomes | Semaglutide has proven CKD benefit (FLOW) | Encouraging but less mature outcomes data |
| HFpEF data | Semaglutide: positive (STEP-HFpEF) | Tirzepatide: positive (SUMMIT) |
| Heart rate | Modest increase possible | Modest increase possible |
So the split is fairly clear: GLP-1 receptor agonists lead on hard outcomes data; tirzepatide leads on average marker improvement. Both matter, but they answer slightly different clinical needs.
Choosing Between Them Based on Patient Phenotype and Risk
Once you know the outcomes data, the next step is matching the drug to the patient's risk pattern.
A simple way to think about it:
- Choose GLP-1 RAs when established ASCVD or CKD is the main concern.
- Choose tirzepatide when obesity, severe insulin resistance, high triglycerides, or major weight loss are the main priority.
For some patients, most of the residual cardiometabolic risk is driven less by established vascular disease and more by ectopic fat, atherogenic dyslipidemia, or metabolic syndrome features. In that setting, tirzepatide's larger metabolic effect can make it the stronger option.
HFpEF is a little less clear-cut because both drug types now have positive data. STEP-HFpEF supports semaglutide, and SUMMIT supports tirzepatide. When both paths are reasonable, the decision often comes down to comorbidities, tolerability, and access.
Safety, Adherence, and Monitoring: Key Differences
These drugs look pretty similar from a side-effect standpoint, especially early on.
For both agents, the most common GI side effects are nausea, vomiting, diarrhea, and constipation, and they tend to show up during dose escalation. Tirzepatide's higher potency means some patients need a slower titration. If GI symptoms are hitting hard, it's reasonable to hold the current dose for another 4 weeks before moving up. Semaglutide has more real-world use and more prescriber familiarity, which can make adherence management a bit smoother in day-to-day care.
One point can't be glossed over: stopping either drug gives back much of the benefit. STEP-4 and SURMOUNT-4 both showed substantial regain after discontinuation. That's why persistence counseling isn't a side issue. It's part of the prescription.
After you choose the drug, follow-up is what turns theoretical benefit into something the patient can keep.
| Monitoring Parameter | Clinical Note |
|---|---|
| Weight and waist circumference | Track trajectory at every visit, not just absolute change |
| Blood pressure and heart rate | Baseline and periodic follow-up; expect modest changes |
| HbA1c and fasting glucose | Baseline and periodic follow-up; watch for glycemic rebound with interruption |
| Lipid panel, including triglycerides | Baseline and every 6–12 months; tirzepatide may warrant closer triglyceride review |
| Renal function and volume status | Baseline and periodic; pay close attention if vomiting or diarrhea occurs |
| GI tolerance during titration | Primary driver of dose adjustment and discontinuation for both agents |
| Gallbladder or pancreatitis symptoms | Ask at each visit; gallbladder events are uncommon but clinically important |
| Retinopathy | In T2D patients with pre-existing retinopathy, monitor symptoms closely and refer if they worsen |
| Adherence and missed doses | Review persistence, missed doses, and any weight regain or glycemic rebound during interruptions |
Both agents carry a boxed warning for thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. That contraindication applies no matter which agent you pick.
Conclusion: What the Evidence Supports in 2026
In 2026, both GLP-1 receptor agonists and tirzepatide lower cardiovascular risk beyond BMI, but they fit different clinical needs. You can see that most clearly in the outcomes data.
In SELECT, weekly semaglutide 2.4 mg cut MACE by 20% (HR 0.80; 95% CI 0.72–0.90) in patients with overweight or obesity, established CVD, and no diabetes. That keeps long-acting GLP-1 RAs as the default option when hard outcomes data carry the most weight, especially for patients with established ASCVD or CKD. Tirzepatide stands out less for trial depth and more for the size of its metabolic effect.
In SURMOUNT-5, tirzepatide led to about 50% greater relative weight loss than semaglutide (20.2% vs. 13.7% at 72 weeks), along with larger gains in cardiometabolic markers. SURPASS-CVOT confirmed cardiovascular safety and noninferiority versus dulaglutide for MACE. That makes tirzepatide a strong fit when residual risk is tied more to obesity-linked metabolic burden, especially in severe obesity, high triglycerides, HFpEF, or poorly controlled diabetes.
The practical takeaway is simple: match the drug to the patient selection criteria and main driver of risk.
Key Points for Prescribers
The choice between these two classes should follow the dominant risk phenotype, not the biggest shift on a lab panel.
- Established ASCVD or CKD as the main concern? A long-acting GLP-1 RA with proven CV indications remains the default choice.
- Severe obesity, high triglycerides, HFpEF, or suboptimal GLP-1 response? Tirzepatide’s dual GIP/GLP-1 mechanism offers a meaningful step up in cardiometabolic risk-factor control.
Beyond drug choice, assess ASCVD risk, eGFR, albuminuria, lipid fractions, hs-CRP, and HF status on a routine basis, not just weight and HbA1c. Persistence also needs to be treated as part of the prescription, because weight regain is common after discontinuation.
Match drug choice to residual risk, then track persistence and cardiometabolic markers. That’s how the evidence starts to show up in patient outcomes.
FAQs
Which is better for heart risk: GLP-1 or tirzepatide?
For cardiovascular risk, semaglutide has the stronger evidence right now.
In the SELECT trial, it cut major adverse cardiovascular events by 20% in patients with obesity and cardiovascular disease, even in people without diabetes.
Tirzepatide also helps improve blood pressure, lipids, and inflammatory markers. That said, the dedicated cardiovascular outcomes data from SURPASS-CVOT are still pending.
Semaglutide also has FDA approval to reduce cardiovascular risk and slow chronic kidney disease progression.
Why isn’t BMI enough to choose treatment?
BMI alone isn’t enough because it doesn’t show a patient’s full metabolic health or cardiovascular risk.
It may help with initial eligibility. But treatment decisions should also look at markers like HbA1c, fasting insulin, HOMA-IR, and lipid levels.
BMI can also miss problems like visceral adiposity, especially in patients with borderline BMIs. And because some therapies offer cardiovascular benefits beyond weight loss, treatment should be based on the patient’s overall risk profile and related conditions.
What tests should I track besides weight?
Besides weight, BMI, and waist circumference, keep an eye on a few other markers to check safety and see how treatment is going.
- Glycemic: HbA1c, fasting plasma glucose, fasting insulin
- Organ function: CMP, creatinine, eGFR, ALT, AST
- Cardiovascular: blood pressure, resting heart rate, lipid panel
It also helps to follow lipase, amylase, TSH, mental health screening, and baseline retinal exams in patients with diabetes.